Início/TMO

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze TMO in workspace
TMONYSE/health care

Thermo Fisher Scientific Inc.

$528.51Up+1,46 (+0,28%)
Research reviewed: 12 de jul. de 2026, 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Thermo Fisher Scientific Inc. operates in Life Sciences Tools and Services within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Ouverture
524,20
Haut
534,73
Bas
521,77
Capitalisation
196,41 Md
Ratio C/B
29.07
Plus haut sur 52 semaines
--
Dividende
0.360%
Dividende trimestriel
--

3-month price context

O gráfico mostra a tendência recente de 3 meses para ajudar usuários a entender a estrutura de curto prazo antes de abrir o workspace completo de pesquisa.

Investment thesis

Base case
Strengthening demand from pharmaceutical and biotechnology customers can improve organic growth across instruments, consumables, and biopharma services. The base case remains conditional on academic and government weakness staying manageable.
Bull case
Strengthening demand from pharmaceutical and biotechnology customers can improve organic growth across instruments, consumables, and biopharma services. The completed Clario acquisition expands Thermo Fisher's clinical research capabilities and creates cross-selling and productivity opportunities within biopharma services. Continued productivity initiatives can support margin expansion even while end-market recovery remains uneven.
Bear case
Muted U.S. and China conditions in academic and government markets can constrain instrument and consumables demand. Slightly declining China revenue and uncertain local funding conditions could delay a broader recovery in Asia-Pacific demand. Debt increased following acquisition activity, raising integration, financing-cost, and capital-allocation risk if expected returns take longer to emerge.
Thesis invalidation
Reassess the thesis if muted U.S. and China conditions in academic and government markets can constrain instrument and consumables demand.

Key catalysts

  • Biopharma demand recovery

    Strengthening demand from pharmaceutical and biotechnology customers can improve organic growth across instruments, consumables, and biopharma services.

  • Clario portfolio expansion

    The completed Clario acquisition expands Thermo Fisher's clinical research capabilities and creates cross-selling and productivity opportunities within biopharma services.

  • Productivity execution

    Continued productivity initiatives can support margin expansion even while end-market recovery remains uneven.

Principal risks

  • Academic and government weakness

    Muted U.S. and China conditions in academic and government markets can constrain instrument and consumables demand.

  • China market exposure

    Slightly declining China revenue and uncertain local funding conditions could delay a broader recovery in Asia-Pacific demand.

  • Acquisition leverage

    Debt increased following acquisition activity, raising integration, financing-cost, and capital-allocation risk if expected returns take longer to emerge.

Latest earnings research

2026 Q1

For the quarter ended March 28, 2026, Thermo Fisher delivered reported revenue and earnings growth, supported by stronger pharma and biotech demand, acquisitions, foreign exchange, and productivity, while academic, government, diagnostics, and China conditions remained mixed.

Valuation interpretation

  • A premium quality case is supported when recurring consumables and services growth combines with sustained productivity and biopharma recovery.
  • Uneven end markets and acquisition-related leverage warrant a discount if organic growth does not strengthen as integration progresses.

Peer research

DHRABBVJNJ

Recent news

Trefis · il y a 5 heures

Alamar Hits A High Note On Alzheimer's Buzz

Simply Wall St. · il y a 6 jours

Thermo Fisher (TMO) Wins FBI Approval For Rapid DNA Tool In Crime Investigations

Zacks · il y a 6 jours

Is ICLR Stock a Value Trap or Turnaround After an Earnings Reset?

Zacks · il y a 7 jours

ICON Stock Outlook 2026 as Margin Woes Meet a Stronger Backlog Base

MedTech Dive · il y a 8 jours

Top 10 medtech deals in the first half of 2026

Zacks · il y a 11 jours

Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?

Data and research sources

Research updated: 12 de jul. de 2026, 00:00 UTC
3 verified sources
Thermo Fisher Scientific Reports First Quarter 2026 ResultsThermo Fisher Scientific Inc. · earningsVerified

Fetched: 12/07/2026, 0:00:00 UTC

Published: 23/04/2026, 00:00:00

Open original source
Thermo Fisher Scientific Investor RelationsThermo Fisher Scientific Inc. · companyVerified

Fetched: 12/07/2026, 0:00:00 UTC

Open original source
Thermo Fisher Scientific Form 10-Q for the Quarter Ended March 28, 2026U.S. Securities and Exchange Commission · filingVerified

Fetched: 12/07/2026, 0:00:00 UTC

Open original source

Continue in the research workspace

Keep TMO in context, run a multi-agent analysis, and monitor thesis changes.

Analyze TMO free

Conheça todo o sistema de análise

Cada etapa tem uma função clara e deixa um resultado auditável.

Metodologia de análiseLer relatórios de mercadoExplorar ações

Continue researching this stock

Analista de Mercado

Analista de Mercado se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Analista Fundamentalista

Analista Fundamentalista se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Analista de Notícias

Analista de Notícias se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Gestor de Risco

Gestor de Risco se especializa na etapa de Monitorar dentro de Risco e monitoramento e organiza o contexto para os próximos papéis.